title: Anti-Müllerian hormone serum values and ovarian reserve: can it predict a decrease in fertility after ovarian stimulation by ART cycles?
abstract: BACKGROUND
  A variety of indicators of potentially successful ovarian stimulation cycles are available, including biomarkers such as anti-Mullerian hormone. The aim of our study was to confirm the usefulness of serum anti-Mullerian hormone assay in predicting ovarian response and reproductive outcome in women eligible for ART cycles.
  
  
  METHODS
  Forty-six women undergoing ART cycles at the Centre for Reproductive Medicine in Parma were recruited from March-to-June 2010.
  
  
  METHODS
  age<42 years; body-mass-index = 20-25; regular menstrual cycles; basal serum FSH concentration <12 IU/L and basal serum estradiol concentration <70 pg/mL. The couples included in our study reported a variety of primary infertility causes. All women underwent FSH stimulation and pituitary suppression (GnRH-agonist/GnRH-antagonist protocols). Women were considered poor-responders if they had ≤ 3 oocytes; normal-responders 4-9 oocytes and high-responders ≥ 10 oocytes. Serum samples for the AMH assays were obtained on the first and last days of stimulation. A P value ≤ 0.05 was considered statistically significant.
  
  
  RESULTS
  FSH levels increased significantly when AMH levels decreased. The total dose of r-FSH administered to induce ovulation was not correlated to AMH. The number of follicles on the hCG, serum estradiol levels on the hCG-day, and the number of retrieved oocytes were significantly correlated to AMH. The number of fertilized oocytes was significantly correlated to the AMH levels. No significant correlation was found between obtained embryos or transferred embryos and AMH. Basal serum AMH levels were significantly higher than those measured on the hCG-day, which appeared significantly reduced. There was a significant correlation between AMH in normal responders and AMH in both high and poor responders.
  
  
  CONCLUSIONS
  Our data confirm the clinical usefulness of AMH in ART-cycles to customize treatment protocols and suggest the necessity of verifying an eventual permanent decrease in AMH levels after IVF.
authors.affiliation: Department of Gynecology, Obstetrics and Neonatology, University of Parma, Parma, Italy. titosilvio.patrelli@gmail.com
authors.forename: Tito Silvio
authors.initials: TS
authors.lastname: Patrelli
authors.forename: Salvatore
authors.initials: S
authors.lastname: Gizzo
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Sianesi
authors.forename: Luca
authors.initials: L
authors.lastname: Levati
authors.forename: Antonio
authors.initials: A
authors.lastname: Pezzuto
authors.forename: Bruno
authors.initials: B
authors.lastname: Ferrari
authors.forename: Alberto
authors.initials: A
authors.lastname: Bacchi Modena
mesh_terms: D000328:Adult; D054304:Anti-Mullerian Hormone / Q000097:blood*; D015415:Biomarkers / Q000378:metabolism; D006063:Chorionic Gonadotropin / Q000378:metabolism; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006801:Humans; D007246:Infertility / Q000628:therapy; D007986:Luteinizing Hormone / Q000378:metabolism; D010053:Ovary / Q000502:physiology*; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D011256:Pregnancy Outcome; D027724:Reproductive Techniques, Assisted
chemical_list: D015415:Biomarkers; D006063:Chorionic Gonadotropin; D054304:Anti-Mullerian Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone